Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare fax automation AI extracting referral and authorization data into EHR workflows; eliminating manual fax processing for medical practices where 80% of communications are still faxed.
Tennr is an AI-powered healthcare operations platform that automates fax-based administrative workflows for healthcare providers — extracting data from incoming faxes (referrals, prior authorizations, lab results, patient records) and automatically routing, categorizing, and populating EHR workflows to eliminate the manual data entry that consumes significant administrative staff time at medical practices and health systems. Founded in 2021 and headquartered in New York, Tennr has raised approximately $18 million targeting the persistent problem of healthcare fax volume, as US healthcare still transmits approximately 80% of inter-provider communications via fax.\n\nTennr's AI system reads incoming fax documents, identifies the document type (referral, authorization request, clinical note), extracts key clinical data (patient name, DOB, diagnosis codes, requested procedures), and automatically creates the corresponding workflows in the practice management or EHR system — eliminating the need for front desk staff to manually read faxes, type data into multiple systems, and track follow-up actions. The platform integrates with major EHR systems (Epic, Athenahealth, eClinicalWorks) to push extracted data directly into the right fields.\n\nIn 2025, Tennr operates in the healthcare administrative AI market alongside Thoughtful AI (healthcare billing automation), Olive AI (now restructured), and general RPA platforms that healthcare organizations adapt for administrative workflows. The healthcare fax automation market is significant — large specialty practices can receive thousands of faxes daily, with each requiring manual processing. Tennr's AI-native approach for healthcare document understanding (trained specifically on medical fax content) differentiates it from generic document AI. The 2025 strategy focuses on expanding to more specialty practices, deepening integrations with more EHR platforms, and adding prior authorization automation as a high-value workflow.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.